PathoQuest is a member of MabDesign, a membership organization dedicated to the creation of a unique environment that allows the economic development and growth of the French industrial sector in the field of therapeutic antibody and immunotherapy.
PathoQuest announced that it has received Propel Certification from Illumina after successfully completing the requirements for achieving this recognition. This included demonstrating the ability to produce high-quality data on the NexSeq System following a streamlined and rigorous process.
Press ReleaseThe company adds experienced executives to support the continued growth of Biologics Genomic Service and Clinical Diagnostics businesses which utilize PathoQuest’s proprietary Next-Generation Sequencing (NGS) based testing solution. PARIS, FRANCE – July...